CLOSE

Subscribe to email alerts

Cannabis Access 21/06/2019

Applied Cannabis Research and Cannabis Access Clinics approved to commence landmark PTSD study

  • Study will examine effects of medicinal cannabis on PTSD sufferers

  • Expected study size of ~300 participants

  • Trial scheduled to begin immediately

  • Patients will be recruited through the Cannabis Access Clinics networks

  • The study measures efficacy of cannabis extract ECs315 supplied by BOD Australia


Applied Cannabis Research is pleased to advise that it has received ethics approval to undertake a study of medicinal cannabis in sufferers of Post Traumatic Stress Disorder (PTSD).

Patient recruitment for the landmark 12 month trial will be facilitated by the Cannabis Access Clinics network.

PTSD is a particular set of reactions that can develop in people who have experienced a traumatic event which threatened their life or safety. As a result, sufferers develop feelings of intense fear, helplessness and horror. It is estimated PTSD affects 12% of Australians.

Participants in the study will receive medicinal cannabis extract ECs315 from product supplier BOD Australia.  Patients will bear standard treatment costs for participating in the study, although they will be eligible for rebates through Medicare and, in some cases, private insurers.

Dr John Barlow, principal researcher at Applied Cannabis Research commented, “Through the TGA, Australia has a stringent medical compliance framework for medicinal cannabis that requires precise dosing and monitoring of patients, making it an ideal location for this type of research. We hope to add to the increasing body of knowledge about medicinal cannabis and the potential for benefit to patients suffering from the effects of traumatic experiences”.

Medical Director for Cannabis Access Clinics Dr. Nijhawan commented: “We have first-hand experience treating symptoms of PTSD and are seeing the positive effects that medicinal cannabis can have on patient outcomes. It is our hope that data from this study will help improve clinical decisions being made by Australian doctors in regards to medicinal cannabis therapies”.

Jo Patterson, CEO of medicinal cannabis supplier BOD, said: “Post Traumatic Stress Disorder is widespread and debilitating on a global scale. This study will provide valuable insight into how medicinal cannabis is being used and its effect on patient outcomes”

Patients interested in being assessed for eligibility in the study can contact Cannabis Access Clinics 1300 991 477 or email info@caclinics.com.au

For more information please contact Applied Cannabis Research on info@appliedcannabisresearch.com.au   or (02) 8294 6406

About Applied Cannabis Research

Applied Cannabis Research is a specialist contract research organisation providing medicinal cannabis companies with services to assess the outcome of using their products to treat patients. Applied Cannabis Research conducts a range of studies including observational and clinical trials.

About Cannabis Access Clinics

Cannabis Access Clinics is the largest network of medicinal cannabis clinics helping patients with chronic conditions such as chronic pain to access better health outcomes and improve their quality of life. Patients can access the national service by telehealth or physical attendance where they will be clinically assessed and prescribed in accordance with Australian Therapeutic Guidelines Administration (TGA) guidelines and State regulations.

Back to News

Related Articles

Cannabis Industry News

Gaps remain in Irish pilot programme despite first shipment of medical cannabis oil

26/08/2019 Read more
BevCanna

BevCanna Awarded Health Canada Cannabis Research License

22/08/2019 Read more
Sequoya

Global Cannabis Provides Update to Exclusive Polish Sales Agreement with Sequoya Cannabis Ltd.

19/08/2019 Read more
Harvest One

Harvest One has GelPell study results published

14/08/2019 Read more

CLOSE

Subscribe to email alerts